GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog...

[cafead]

via GlaxoSmithKline has boosted its challenge for the anemia due to chronic kidney disease market, revealing a clean sweep of hits on key endpoints across two phase 3 clinical trials. But with the FDA rejecting AstraZeneca’s rival drug, doubts remain about GSK’s chances of getting to market.

article source